Top-News

Lixte Biotechnology News

Keine aktuellen Kursdaten verfügbar
ISIN: US5393191037
US-Symbol: LIXT
Typ: Aktie

Lixte Biotechnology News

10.02.23 - PR Newswire
Thinking about buying stock in Hillstream Biopharma, LYFT, C3.ai, Lixte Biotechnology, or Salesforce?
Thinking about buying stock in Hillstream Biopharma, LYFT, C3.ai, Lixte Biotechnology, or Salesforce? PR Newswire
13.04.22 - PR Newswire
WallachBeth Capital Announces Purchase and Sale of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT)
WallachBeth Capital Announces Purchase and Sale of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) PR Newswire
12.04.22 - PR Newswire
Thinking about buying stock in Lixte Biotechnology, Hoth Therapeutics, Ocugen, Bilibili, or Sunshine Biopharma?
Thinking about buying stock in Lixte Biotechnology, Hoth Therapeutics, Ocugen, Bilibili, or Sunshine Biopharma? PR Newswire
05.01.22 - PR Newswire
Thinking about buying stock in Lixte Biotechnology, Data Storage, Castlight Health, Cleveland-Cliffs, or Caladrius Biosciences?
Thinking about buying stock in Lixte Biotechnology, Data Storage, Castlight Health, Cleveland-​Cliffs, or Caladrius Biosciences? PR Newswire
01.12.20 - PR Newswire
WallachBeth Capital Announces Completion of $5.7 Million Joint Underwritten Public Offering for Lixte Biotechnology Holdings, Inc.
WallachBeth Capital Announces Completion of $5.7 Million Joint Underwritten Public Offering for Lixte Biotechnology Holdings, Inc. PR Newswire
06.08.19 - GlobeNewswire
The Spanish Sarcoma Group Will Lead a European Consortium to Evaluate the Ability of Lixte Biotechnology Holdings’ LB-100 to Improve First Line Therapy for Advanced Soft Tissue Sarcomas
EAST SETAUKET, N.Y., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. ( OTCQB: LIXT ) announced that it signed a clinical trial agreement with the Spanish ...
30.12.15 - PR Newswire
Lixte Biotechnology Holdings, Inc. Announces Exclusive Licensing Of Their Lead Anti-Cancer Compound LB-100 For Potential Treatment Of Hepatocellular Carcinoma In Asia To Taipei Medical University
Lixte Biotechnology Holdings, Inc. Announces Exclusive Licensing Of Their Lead Anti-​Cancer Compound LB-100 For Potential Treatment Of Hepatocellular Carcinoma In Asia To ...
17.09.15 - PR Newswire
Lixte Biotechnology Holdings, Inc. Engages BioPharmaWorks LLC To Enhance Development Of Its Pipeline Of Novel Compounds
Lixte Biotechnology Holdings, Inc. Engages BioPharmaWorks LLC To Enhance Development Of Its Pipeline Of Novel Compounds PR Newswire
18.06.14 - PR Newswire
Lixte's Lead Compound LB-100 Reported To Enhance Chemotherapy Effectiveness In Animal Models Of Liver Cancer
Lixte's Lead Compound LB-100 Reported To Enhance Chemotherapy Effectiveness In Animal Models Of Liver Cancer PR Newswire
25.04.13 - PR Newswire
Lixte Biotechnology Announces Initiation Of A Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100
Lixte Biotechnology Announces Initiation Of A Phase I Trial Of Its Lead Anti-​Cancer Compound, LB-100 PR Newswire
27.11.12 - PR Newswire
Lixte Biotechnology Holdings Announces New Appointment To Board Of Directors
Lixte Biotechnology Holdings Announces New Appointment To Board Of Directors PR Newswire
31.07.12 - PR Newswire
Lixte Biotechnology Holdings Announces Increased Funding And FDA Allowance To Conduct A Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100
Lixte Biotechnology Holdings Announces Increased Funding And FDA Allowance To Conduct A Phase I Trial Of Its Lead Anti-​Cancer Compound, LB-100 PR Newswire

Newssuche

Videos

newspaper
16.04.24 +5,00%
Technical Trading: Natural Gas Long Chance
Erdgas Long Typ: Turbo Open End WKN: VM6KAH Hebel: 2,11 Laufzeit: OpenEnd Einstieg: Market ... Mehr »